Supplementary Online Content

Czarnetzki C, Elia N, Frossard J-L, et al. Erythromycin for gastric emptying in patients undergoing general anesthesia for emergency surgery: a randomized clinical trial. *JAMA Surg*. Published online June 17, 2015. doi:10.1001/jamasurg.2015.0306.

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Patient demographics and baseline characteristics for each stratum

	Trauma		Non-trauma	
	Erythromycin (n=33)	Placebo (n=33)	Erythromycin (n=33)	Placebo (n=33)
Age, years	41 (32-60)	48 (33-55)	40 (31-55)	42 (29-51)
Female	8 (24%)	9 (27%)	14 (42%)	12 (36%)
Bodyweight, kg	71 (64-80)	78 (70-83)	77 (65-80)	78 (66-85)
Bodyheight, cm	172 (165-182)	176 (170-183)	173 (163-180)	172 (168-180)
Body-mass index	23.7 (22.0-26.6)	24.8 (23.2-27.8)	25.8 (22.7-28.3)	25.3 (23.2-27.8)
Time since last solid meal, hr	9.5 (7.8-178)	8.3 (6.3-13.9)	20.3 (12.4-28.1)	20.3 (17.4-37.7)
Time since last liquid intake, hr	7.5 (6.1-9.3)	7 (5.5-9.7)	13.4 (6.8-20.7)	17.2 (7.0-26.0)
Pain, visual analogue scale 0-100	40 (20-60)	50 (0-60)	20 (0-50)	20 (0-50)
Blood glucose, mmol/L	5.7 (5.1-6.4)	5.9 (5.3-6.7)	5.5 (5.1-6.3)	5.4 (4.9-6.2)
Patients receiving antacides preoperatively	1 (3%)	4 (12%)	15 (45%)	16 (48%)
Patients receiving opiates preoperatively	27 (82%)	28 (85%)	7 (21%)	7 (21%)
Injury Severity Score (trauma only)	4 (4-9)	4 (4-10)	n/a	n/a
Diagnosis (non-trauma only)				
Appendicitis	n/a	n/a	23 (69.7%)	26 (78.8%)
Cholecystitis	n/a	n/a	2 (6.1%)	3 (9.1%)
Other abdominal	n/a	n/a	1 (3.0%)	1 (3.0%)
Other non-abdominal	n/a	n/a	7 (21.2%)	3 (9.1%)

Data are median (interquartile range) or number (%). The body-mass index is the weight in kilograms divided by the square of the height in meters. Pain and glycemia were measured at arrival in the operating room. n/a=not applicable.

eTable 2. Proportion of patients with residual liquid or solid stomach content and volume of residual stomach content

		Placebo Group (n=66)		Erythromycin Group (n=66)		Difference in proportions	Difference in volumes
		N° pat (%)	Volume ml median (IQR)	N° pat (%)	Volume ml median (IQR)	% (95%CI)	P value
All patients with residual stomach content	**Total**	**42 (63.3%)**	**43.5 (15.0-100)**	**26 (39.4%)**	**27.5 (10.0-75.0)**	**-24.2 (-40.8 to -7.7)**	**0.380**
	Liquid	30 (71.4%)	30 (10-100)	15 (57.7%)	15 (5-25)	-13.7 (-37.1 to 9.7)	0.053
	Solid	3 (7.14%)	200 (200-300)	5 (19.2%)	60 (40-150)	12.1 (-4.9 to 29.1)	0.136
	Both	9 (21.4%)	70 (42-170)	6 (23.1%)	150 (70-450)	1.6 (-18.8 to 22.1)	0.289
		Placebo Group (n=33)		**Erythromycin Group (n=33)**		**Difference in proportions**	**Difference in volumes**
		N° pat (%)	Volume ml median (IQR)	N° pat (%)	Volume ml median (IQR)	% (95%CI)	P value
Trauma patients with residual stomach content	**Total**	**23 (69.7%)**	**70 (30-200)**	**18 (54.5%)**	**50 (10.0-150.0)**	**-15.2 (-7.9 to 38.2)**	**0.203**
	Liquid	13 (56.5%)	30 (15-100)	8 (44.4%)	10 (7.0-32.5)	-12.1 (-42.7 to 18.5)	0.128
	Solid	3 (13.0%)	200 (200-300)	4 (22.2%)	105 (50.0-300)	9.2 (-14.4 to 32.8)	0.216
	Both	7 (30.4%)	70 (45-300)	6 (33.3%)	150 (70-450)	2.9 (-25.9 to 31.7)	0.568
Non-trauma patients with residual stomach content	**Total**	**19 (57.6%)**	**26 (10-100)**	**8 (24.2%)**	**15.5 (10-25)**	**-33.4 (11.1 to 55.7)**	**0.006**
	Liquid	17 (89.5%)	30 (10-100)	7 (87.5%)	15 (5-20)	-2.0 (-28.7 to 24.8)	0.193
	Solid	0 (0.0%)		1 (12.5%)	30	12.5 (-10.4 to 35.4)	-
	Both	2 (10.5%)	18 (10-26)	0 (0.0%)		-10.5 (-24.3 to 3.27)	-

Volume of liquid that could be aspirated through the working channel of the endospcope was measured, volume of solid was estimated. P-values from Kurskal-Wallis rank test.

eTable 3. Adverse Events

	Placebo (n=66)	Erythromycin (n=66)	Odds ratio (95% CI)	P Value
Stomach cramps	4 (6.1%)	20 (30.0%)	6.74 (2.04-28.6)	<0.001
Nausea before induction	2 (3.0%)	15 (22.7%)	9.41 (2.01-87.3)	0.001
Vomiting before induction	0	1 (1.5%)	n.a.	0.318

Data are number of patients with event (% of patients). CI=confidence interval. n.a. = not applicable